BioCurex Inc, formerly Whispering Oakes International, announced on January 10th that it signed a licensing agreement for the company’s RECAF materials and technologies with Inverness Medical Innovations Inc. This agreement comes on the heels of a similar agreement with Abbott Laboratories in the fourth quarter of 2007. BioCurex’s patented RECAF technology provides the potential for fast and accurate cancer detection that can be used to diagnose prostate, breast, lung, colorectal and other types of cancer. Early detection and the proper diagnosis are keys to prolonging and enriching lives of cancer patients worldwide.
BioCurex and Abbott Laboratories were able to present the results of RECAF studies at the International Society for the Oncodevelopmental Biology and Medicine (ISOBM) conference in Richmond, British Columbia. These studies showed the abilities of RECAF to separate cancer from normal sera at a 95.4% effective rate.
After the presentation Ricardo Moro, President and CEO of BioCurex stated, “These presentations to the ISOBM validate our joint efforts to develop the RECAF assay in the chemoluminescence format used by high throughput automated instruments. These results correlate with those in previous presentations and provide additional support for the effectiveness of the RECAF technology. This presentation will, no doubt, trigger a positive response from the scientific community and demonstrates to our shareholders that we are steadily progressing toward the commercialization of the technology.”
The company has set the lofty goal of gaining a minimum of 25% market share within the next 5 years, with the hopes that their RECAF products will replace most other tests on the market. These aspirations may not be hard to accomplish since RECAF has been proven to detect all cancers with 90% sensitivity. The company is well positioned with two of the biggest companies in the industry and looks forward to the not so distant future.
Let us hear your thoughts below: